New therapeutic concepts in bile acid transport and signaling for management of cholestasis

The identification of the key regulators of bile acid (BA) synthesis and transport within the enterohepatic circulation has revealed potential targets for pharmacological therapies of cholestatic liver diseases. Novel drug targets include the bile BA receptors, farnesoid X receptor and TGR5, the BA‐induced gut hormones, fibroblast growth factor 19 and glucagon‐like peptide 1, and the BA transport systems, apical sodium‐dependent bile acid transporter and Na+‐taurocholate cotransporting polypeptide, within the enterohepatic circulation. Moreover, BA derivatives undergoing cholehepatic shunting may allow improved targeting to the bile ducts. This review focuses on the pathophysiological basis, mechanisms of action, and clinical development of novel pharmacological strategies targeting BA transport and signaling in cholestatic liver diseases. (Hepatology 2017;65:1393‐1404).

[1]  J. Reguła,et al.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.

[2]  Hanns-Ulrich Marschall,et al.  Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. , 2016, Cell metabolism.

[3]  M. Trauner,et al.  Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease , 2016, Digestive Diseases.

[4]  T. Baumert,et al.  Hepatitis B virus receptors and molecular drug targets , 2016, Hepatology International.

[5]  A. Baghdasaryan,et al.  Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. , 2016, Journal of hepatology.

[6]  J. Lupski,et al.  Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis , 2016, Nature Communications.

[7]  M. Kowgier,et al.  Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes , 2016, Alimentary pharmacology & therapeutics.

[8]  R. M. Learned,et al.  Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice , 2015, Hepatology.

[9]  A. Moschetta,et al.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23 , 2015, Nature Reviews Drug Discovery.

[10]  D. Häussinger,et al.  TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro , 2015, Gut.

[11]  O. Barbier,et al.  Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease , 2015, Scientific Reports.

[12]  J. Boyer,et al.  Fibrates and cholestasis , 2015, Hepatology.

[13]  D. Cassio,et al.  Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4‐phenylbutyrate , 2015, Hepatology.

[14]  F. Bäckhed,et al.  Farnesoid X Receptor Inhibits Glucagon-Like Peptide-1 Production by Enteroendocrine L-cells , 2015, Nature Communications.

[15]  U. Beuers,et al.  Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na+-taurocholate cotransporting polypeptide knockout mice , 2015, Hepatology.

[16]  M. Trauner,et al.  New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. , 2015, Journal of hepatology.

[17]  K. Lindor,et al.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.

[18]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[19]  D. Adams,et al.  Novel therapeutic targets in primary biliary cirrhosis , 2015, Nature Reviews Gastroenterology &Hepatology.

[20]  H. Verkade,et al.  Bile Acid Pool Dynamics in Progressive Familial Intrahepatic Cholestasis With Partial External Bile Diversion , 2015, Journal of pediatric gastroenterology and nutrition.

[21]  V. Balasubramaniyan,et al.  Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. , 2015, Journal of hepatology.

[22]  D. Brenner,et al.  Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance , 2015, Nature Medicine.

[23]  I. Albert,et al.  Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. , 2015, The Journal of clinical investigation.

[24]  H. Waterham,et al.  Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype , 2015, Hepatology.

[25]  D. Lindhout,et al.  A nontumorigenic variant of FGF19 treats cholestatic liver diseases , 2014, Science Translational Medicine.

[26]  H. Mellor,et al.  Targeted inhibition of the FGF19‐FGFR4 pathway in hepatocellular carcinoma; translational safety considerations , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[27]  T. Arora,et al.  Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. , 2014, Cancer research.

[28]  T. Tordjmann,et al.  The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice , 2013, Hepatology.

[29]  A. Lohse,et al.  The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. , 2013, Journal of hepatology.

[30]  F. Cattaruzza,et al.  The TGR5 receptor mediates bile acid-induced itch and analgesia. , 2013, The Journal of clinical investigation.

[31]  S. Kliewer,et al.  Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[32]  F. Bäckhed,et al.  Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. , 2013, Cell metabolism.

[33]  M. Trauner,et al.  Bile acid transporters and regulatory nuclear receptors in the liver and beyond , 2013, Journal of hepatology.

[34]  J. Boyer,et al.  Molecular pathogenesis of cholestasis. , 2012, The New England journal of medicine.

[35]  H. Sokol,et al.  Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases , 2012, Gut.

[36]  J. Reguła,et al.  Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease , 2012, BMC Research Notes.

[37]  M. Trauner,et al.  Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. , 2012, Gastroenterology.

[38]  S. Spiegel,et al.  Conjugated bile acids activate the sphingosine‐1‐phosphate receptor 2 in primary rodent hepatocytes , 2012, Hepatology.

[39]  C. Paulusma,et al.  A biliary HCO3− umbrella constitutes a protective mechanism against bile acid‐induced injury in human cholangiocytes , 2012, Hepatology.

[40]  A. Baghdasaryan,et al.  Dual farnesoid X receptor/TGR5 agonist INT‐767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO  3− output , 2011, Hepatology.

[41]  A. S. Andreasen,et al.  Type 2 Diabetes Is Associated with Altered NF-κB DNA Binding Activity, JNK Phosphorylation, and AMPK Phosphorylation in Skeletal Muscle after LPS , 2011, Front. Nutr..

[42]  S. Kliewer,et al.  The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. , 2011, Molecular endocrinology.

[43]  S. Kliewer,et al.  FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis , 2011, Science.

[44]  Lincoln D. Stein,et al.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. , 2011, Cancer cell.

[45]  M. Trauner,et al.  Nuclear receptors in liver disease , 2011, Hepatology.

[46]  G. Hirschfield,et al.  Pathogenesis of cholestatic liver disease and therapeutic approaches. , 2010, Gastroenterology.

[47]  R. D. de Man,et al.  The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: Results of a double‐blind, randomized, placebo‐controlled trial , 2010, Hepatology.

[48]  C. Wijmenga,et al.  Genome-wide association analysis in primary sclerosing cholangitis. , 2010, Gastroenterology.

[49]  D. Häussinger,et al.  The membrane‐bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders , 2009, Hepatology.

[50]  D. Gouma,et al.  High expression of the bile salt‐homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis , 2009, Hepatology.

[51]  B. M. Forman,et al.  Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response , 2008, Hepatology.

[52]  D. Häussinger,et al.  Expression and function of the bile acid receptor TGR5 in Kupffer cells. , 2008, Biochemical and biophysical research communications.

[53]  Richard J. Thompson,et al.  Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. , 2008, Gastroenterology.

[54]  F. Lammert,et al.  Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. , 2007, Gastroenterology.

[55]  S. Glaser,et al.  Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. , 2007, Gastroenterology.

[56]  J. Auwerx,et al.  Endocrine functions of bile acids , 2006, The EMBO journal.

[57]  S. Kliewer,et al.  Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[58]  K. Zatloukal,et al.  24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. , 2006, Gastroenterology.

[59]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[60]  R. Blevins,et al.  Farnesoid X Receptor Activates Transcription of the Phospholipid Pump MDR3* , 2003, Journal of Biological Chemistry.

[61]  K. Zatloukal,et al.  Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. , 2003, Gastroenterology.

[62]  Masataka Harada,et al.  A G Protein-coupled Receptor Responsive to Bile Acids* , 2003, The Journal of Biological Chemistry.

[63]  H. Ackermann,et al.  The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study , 2002, European journal of gastroenterology & hepatology.

[64]  Takao Nakamura,et al.  Identification of membrane-type receptor for bile acids (M-BAR). , 2002, Biochemical and biophysical research communications.

[65]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[66]  G. Frantz,et al.  A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. , 2002, The American journal of pathology.

[67]  P. Fisher,et al.  Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. , 2001, Molecular biology of the cell.

[68]  M. Makishima,et al.  Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor* , 2001, The Journal of Biological Chemistry.

[69]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[70]  A. Hofmann,et al.  The continuing importance of bile acids in liver and intestinal disease. , 1999, Archives of internal medicine.

[71]  A. Hofmann,et al.  Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. , 1999, Gastroenterology.

[72]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[73]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[74]  Jasmine Chen,et al.  Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.

[75]  J. Steinbach,et al.  Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents. , 1986, Gastroenterology.

[76]  B. Combes,et al.  Beneficial effect of cholestyramine in sclerosing cholangitis. , 1980, Gastroenterology.

[77]  P. Chiba,et al.  Metabolic preconditioning protects BSEP/ABCB11-/- mice against cholestatic liver injury. , 2017, Journal of hepatology.

[78]  M. Trauner,et al.  Bile acids in regulation of inflammation and immunity: friend or foe? , 2016, Clinical and experimental rheumatology.

[79]  A. Miethke,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Pharmacological Inhibition of Apical Sodium- Dependent Bile Acid Transporter Changes Bile Composition and Blocks Progression of Sclerosing Cholangitis in Multidrug Resistance 2 Knockout Mice , 2016 .

[80]  S. Raimondo,et al.  Invariant NKT cells are expanded in peripheral blood but are undetectable in salivary glands of patients with primary Sjögren's syndrome. , 2016, Clinical and experimental rheumatology.

[81]  H. Gohlke,et al.  α5β1‐integrins are sensors for tauroursodeoxycholic acid in hepatocytes , 2013, Hepatology.

[82]  H. Jaeschke,et al.  Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. , 2011, The American journal of pathology.

[83]  B. Staels,et al.  Role of bile acids and bile acid receptors in metabolic regulation. , 2009, Physiological reviews.

[84]  R. Porte,et al.  Altered bile composition after liver transplantation is associated with the development of nonanastomotic biliary strictures. , 2009, Journal of hepatology.

[85]  K. Zatloukal,et al.  Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice , 2009, Hepatology.